http://www.cnr.it/ontology/cnr/individuo/prodotto/ID10304

Fluvoxamine treatment and D(2) receptors: a PET study on OCD drug-naive patients (Articolo in rivista)

Type

Label

Fluvoxamine treatment and D(2) receptors: a PET study on OCD drug-naive patients (Articolo in rivista) (literal)

Anno

Alternative label

Moresco R.M. 1,2,3, Pietra L. 2, Henin M. 4, Panzacchi A .3, Locatelli M. 4, Bonaldi L. 1, Carpinelli A. 1,2,3, Gobbo C. 3, Bellodi L. 4,5, Perani D. 1,5, Fazio F. 1,2,3 (2007)
Fluvoxamine treatment and D(2) receptors: a PET study on OCD drug-naive patients
in Neuropsychopharmacology (N.Y. N.Y.)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Moresco R.M. 1,2,3, Pietra L. 2, Henin M. 4, Panzacchi A .3, Locatelli M. 4, Bonaldi L. 1, Carpinelli A. 1,2,3, Gobbo C. 3, Bellodi L. 4,5, Perani D. 1,5, Fazio F. 1,2,3 (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1. Institute of Molecular Bioimaging and Physiology National Research Council, Milan, Italy 2. Department of Nuclear Medicine, University of Milan-Bicocca, Milan, Italy 3. Department of Nuclear Medicine, Scientific Institute H San Raffaele, Milan, Italy 4. Department of Psychiatry, Scientific Institute H San Raffaele, Milan, Italy 5. Università Vita Salute San Raffaele, Milan, Italy (literal)

Titolo

Fluvoxamine treatment and D(2) receptors: a PET study on OCD drug-naive patients (literal)

Abstract

Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naïve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.55.2, 6.96.9, and 9.99.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p<0.01) to values closer to those observed in the group of normal subjects. Chronic treatment with fluvoxamine induces a slight but significant increase in striatal [11C]Rac BP of previously drug-naïve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity. (literal)

Prodotto di